Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics develops peptide-based therapeutics using a proprietary discovery platform, with programs spanning inflammation and immunology, hematology and metabolic disease. Company news centers on ICOTYDE™ (icotrokinra), an oral IL-23 receptor-targeted peptide approved for moderate-to-severe plaque psoriasis, and rusfertide, a hepcidin mimetic peptide for polycythemia vera developed with Takeda.
Recurring updates also cover collaboration economics with Johnson & Johnson's Janssen Biotech and Takeda, clinical and regulatory milestones, R&D spending on wholly owned discovery programs, financial results, investor conference participation and equity-based inducement awards under Nasdaq rules.
Protagonist Therapeutics (Nasdaq:PTGX) has appointed Sarah O'Dowd as an independent director on its Board, enhancing its governance with her extensive experience in the biopharmaceutical sector. O'Dowd's previous roles include key positions at Lam Research and FibroGen. She replaces Chaitan Khosla, who is stepping down. CEO Dinesh V. Patel emphasized her strategic expertise as vital for Protagonist's growth, particularly with its clinical assets focused on hematology/oncology and inflammatory bowel diseases. O'Dowd expressed eagerness to contribute to Protagonist's vision during this growth phase.
Protagonist Therapeutics (PTGX) reported its Q2 2020 financial results, highlighting significant advancements in its clinical programs. The company moved three candidates into Phase 2 trials, including PTG-300 for polycythemia vera and two oral candidates for inflammatory bowel disease. Financially, PTGX raised $122 million through a secondary offering and has sufficient resources to fund operations through mid-2023. The net loss for Q2 was $19.4 million, improving from $29.2 million the previous year. Revenue from collaborations rose to $6.2 million this quarter, compared to a loss in revenue last year.
On June 17, 2020, Protagonist Therapeutics (Nasdaq: PTGX) announced that the FDA granted Orphan Drug Designation for PTG-300, a synthetic peptide mimetic for treating polycythemia vera (PV). This milestone highlights PTG-300's potential to address patient needs in PV treatment. The Phase 2 results showed a robust clinical response with effective hematocrit control. The FDA’s designation provides benefits like marketing exclusivity and tax credits, vital for developing treatments for rare diseases affecting under 200,000 patients in the U.S.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced that Dinesh V. Patel, Ph.D., President and CEO, will participate in a fireside chat at the BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 p.m. EDT. The event will be accessible via a live and archived webcast on the company’s Investors section of its website. Protagonist is known for its proprietary technology platform aimed at developing novel peptide-based therapeutics, including three clinical-stage assets like PTG-300 and PTG-200.